Medtech start-up credentis has strengthened its board and expanded the company’s dental expertise with the appointment of Dr Michael Peetz as a member of the board of directors.
At its annual general assembly, credentis ag elected Dr. Michael Peetz as a new member of the board of directors, expanding its expertise in the field of dentistry. Peetz studied pharmacy in Munich and Austin, Texas. After an extended stay in the US to pursue his research in San Francisco, he joined the pharmaceutical company Hoechst (now Sanofi-Aventis) in the clinical research department. Peetz held several positions at Geistlich Biomaterials between 1990 and 2008, including CEO. From 2008 to 2012, he was CEO of Camlog Biotechnologies in Basel, an international leader in implant dentistry with a worldwide distribution network.
Peetz was also co-founder and director of the Osteology Foundation in Lucerne, a foundation that deals with research and education in regenerative dentistry. Since 2012, he has been president of Digital Dental Life AG, specialising in the licensing of its web technology to the Dental Campus Association for the online training of dentists in implantology.
Products
The patented Curolox technology is based on peptides self-assembling into a matrix, triggering a biomimetic mineralisation and repair mechanism. The breakthrough is the basis for several innovative credentis products. CurodontRepairprovides dentists with a non-invasive option for natural mineralisation rather than traditional repair of carious lesions. Applied to an early lesion, Curodont Repairforms a scaffold within the lesion to allow new hydroxyapatite crystals to form and grow. Ideally, the lesion will mineralise within several weeks. This effect is observed in a growing number of patients both in clinical studies and daily practice settings. Curodont Repairshows tremendous potential in the treatment of early dental caries. Curodont Protectuses the Curolox technology to protect the tooth surface from acid attack and to treat unpleasant tooth sensations. According to CEO Dominik Lysek: “Curodont Protect has its main benefit in prophylaxis and in the treatment of dental hypersensitivity.”
The clinical data obtained in proof-of-concept clinical studies present a milestone for credentis, showing the successful in-depth treatment of tooth decay. With its regenerative product line, credentis has launched a trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions, thus avoiding frequent recalls by dentists and hygienists.
About credentis ag
The company has its headquarters in the Technopark Aargau. It has won multiple awards and support from organisations such as Genilem and funding from the Swiss National Fund, Aargauer Forschungsfond and Medical Technologies IKC/University of Leeds.
Please login or sign up to comment.
Commenting guidelines